Literature DB >> 25769598

Usefulness of high-sensitivity troponin I for the monitoring of subclinical acute cellular rejection after cardiac transplantation.

K T Ahn1, J-O Choi1, G Y Lee1, H-D Park2, E-S Jeon3.   

Abstract

BACKGROUND: There are conflicting data about the role of cardiac troponin I (cTnI) as determined by means of conventional methods for the prediction of acute rejection after heart transplantation (HT). The purpose of this study was to evaluate whether cTnI as measured by means of the early prototype high-sensitivity assay (hs-cTnI) can predict acute rejection episode after HT compared with grade of rejection in endomyocardial biopsy (EMB).
METHODS: This was a single-center cross-sectional study evaluating cTnI levels with the use of both hs-cTnI and current less sensitive conventional cTnI (conv-cTnI) assays measured at the time of EMB after HT. We calculated an index ratio of observed cTnI to expected mean cTnI for each individual patient defined as the mean cTnI measurements at EMB 60 days after HT.
RESULTS: A total of 252 biopsies from 47 patients were included in this study. In the multivariable mixed model analysis in relation to the presence of acute rejection 60 days after HT, hs-cTnI level was significantly related to the presence of rejection (P = .010). The hs-cTnI ratio index was significantly higher at the time of rejection (median, 1.37; interquartile range [IQR], 1.23-2.88) compared with those without rejection (median, 0.90; IQR, 0.51-1.16; P < .001). In receiver operating characteristic curve analysis, an hs-cTnI ratio index of ≥1.17 could predict the acute rejection with a sensitivity of 82.4% and a specificity of 77.1%.
CONCLUSIONS: An increased hs-cTnI ratio index was significantly related to rejection episodes. Serial monitoring of hs-cTnI and comparing it with the values without rejection might be useful for the detection of acute rejection after HT.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25769598     DOI: 10.1016/j.transproceed.2014.10.049

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  5 in total

Review 1.  Elevated Cardiac Troponin to Detect Acute Cellular Rejection After Cardiac Transplantation: A Systematic Review and Meta-Analysis.

Authors:  Zhengyang Liu; Luke A Perry; Jahan C Penny-Dimri; Michael Handscombe; Isabella Overmars; Mark Plummer; Reny Segal; Julian A Smith
Journal:  Transpl Int       Date:  2022-06-08       Impact factor: 3.842

Review 2.  Advances in diagnostics for transplant rejection.

Authors:  Michael Nasr; Tara Sigdel; Minnie Sarwal
Journal:  Expert Rev Mol Diagn       Date:  2016-10       Impact factor: 5.225

3.  The evolution of patient-specific precision biomarkers to guide personalized heart-transplant care.

Authors:  Mario C Deng
Journal:  Expert Rev Precis Med Drug Dev       Date:  2020-10-28

4.  Role of Soluble ST2 as a Marker for Rejection after Heart Transplant.

Authors:  Ga Yeon Lee; Jin-Oh Choi; Eun-Seon Ju; Yoo-Jung Lee; Eun-Seok Jeon
Journal:  Korean Circ J       Date:  2016-11-01       Impact factor: 3.243

5.  C-Reactive protein level and left ventricular mass are associated with acute cellular rejection after heart transplant.

Authors:  Débora Cestari Bacal; Miguel Morita Fernandes-Silva; Sandrigo Mangini; Marcia Santos de Jesus; Fernando Bacal
Journal:  Clinics (Sao Paulo)       Date:  2021-12-06       Impact factor: 2.365

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.